Search results
Results from the WOW.Com Content Network
Alchemist Group is an Indian conglomerate which has a presence in multiple sectors, including healthcare, pharmaceuticals, food-processing, real estate, infrastructure and tea estates.
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. [3] Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4]
KRIBHCO was incorporated on 17 April 1980 as a national level Multi State Cooperative Society under the central ministry of cooperative by Paul Pothen to implement first gas based high capacity Fertilizer Complex consisting of 2 x 1890 MTPD Ammonia plants and 4 x 1662.5 MTPD Urea plants each with annual installed capacity of 8.91 Lakh MT Ammonia and 14.52 lakh MT of Urea at Hazira District ...
From January 2008 to December 2012, if you bought shares in companies when Jean-Pierre Garnier joined the board, and sold them when he left, you would have a 7.0 percent return on your investment, compared to a -2.8 percent return from the S&P 500.
In 2019 Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa. [ 18 ] In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore.
Genome Therapeutics Corp. was an early biotech company. It was founded in 1961 by Orrie M. Friedman under the name Collaborative Research Inc. [ 1 ] Under the leadership of Helen Donis-Keller and using internal funds, the company produced one of the first linkage maps of the whole human genome in the mid-1980s.
The new public company was named CanniMed Therapeutics, and had Cannimed Ltd. and Prairie Plant Systems as subsidiaries. In March 2017, it announced a deal to distribute its products with PharmaChoice, a Canadian co-operative pharmacy chain. [16] In April 2017, it announced a $10 million expansion of its facility in Saskatoon. [15]
The Novozymes class A share capital is held by Novo Holdings A/S, a wholly owned subsidiary of the Novo Nordisk Foundation. In addition, Novo A/S holds 5,826,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 70.1% of the votes.